Abstract:Observing the safety and effectiveness of CT-guide Ad-P53 intratumoral injection to treat patient with recurrent and metastatic gynecologic cancer who underwent local radiation therapy and veinal chemotherapy without other treatment. From October 2012 to December 2015, the Gynecological Radiation Oncology Division, of the First Affiliated Hospital of Xi’an Jiaotong University treated 122 patients with recurrent and metastatic pelvic tumor, of which 47 received local radiation therapy and veinal chemotherapy before having CT-guide Ad-P53 therapy with local multi-point injection into tumor. In each injection, one (1012VP, viral particles) to four medicines was used and diluted to 4-16ml with normal saline; administrated once per week, for 1-6 times altogether. Forty-seven patients received treatment 91 times in total, with dosage of 2±1 pieces on average. The treatment was performed with no radiation therapy and chemotherapy, and considered to end when the tumor regressed or the patient could not tolerate other treatment. Therapeutic evaluation: (1) objective therapeutic evaluation: The efficacy was evaluated one month after treatment according to WHO (Response Evaluation Criteria in Solid Tumors), in combination with the maximum sectional area of the tumor measured through pelvis MRI scan and the regression rate (%) obtained. The safety of implant needle by the CT scan was also observed. (2) Subjective therapeutic evaluation: It was based on the extent of pain relief and vaginal discharge of the patient. 47 patients were follow-up to 27 months and median follow-up time of 11 months by February 2016. Their generation material listed Table 1. No patient had blood vessels, colorectal, bladder and ureter injury resulting from injection medicines by CT-guide. Forty patients (85.1%) had high fever (≥38.5°C) transitorily. Therapeutic evaluation both subjective and objective was made one month after treatment. The results showed that pain and vaginal discharge achieved notable remission of 41 patients (87.2%) and 22 patients (22/27, 81.5%), respectively. 37 patients (78.7%) had appetite and sleeping improved. The objective clinical benefit ratio (CR+PR+SD> one month) of 80.9% (38/47), see Table 2. The median survival time of 11.6 months; 40 ( 85.1%) patients experienced worsen conditions with median progression-free survival of five months. 4 patients whose appetite and sleeping quality were improved after treatment received palliative chemotherapy again. 22 patients (46.8%) died. CT-guide Ad-P53 local injection therapy helps recurrent and metastatic gynecological patients to have effective pain relief, improve quality of life, and showed high safety level. The use of virus vector comes with certain side effect such high fever while the disease remission was shorter. Hence further clinical study and vital fundamental researches are needed on how to conduct gene therapy in a safe and effective way.

Clinical Effect of Recombinant Adenovirus-p53 Combined with Hyperthermia for Advanced Soft Tissue Sarcoma

Clinical Observation of the Effect of Recombinant Adenovirus-p53 plus Radio-thermotherapy on Soft Tissue Sarcoma

Clinical Effectiveness of Recombinant Adenovirus-P53 Combined with Radiotherapy in Advanced Soft Tissue Sarcoma: A Report of 37 Cases

Clinical efficacy and safety of recombinant adenovirus-p53 combined with concurrent radiotherapy and hyperthermia in treatment of advanced soft tissue sarcoma:a study of 76 patients

Short-term Efficacy of Advanced Malignant Cancer by Gendicine Combined with Chemotherapy

[Recombinant Adenovirus-P53 Gene Therapy Combined with Radiotherapy for Head and Neck Squamous-Cell Carcinoma].

Recombinant adenovirus-p53 gene therapy for advanced unresectable soft tissue sarcomas.

726. Clinical Trial of Recombinant Adenovirus-p53 (Gendicine) Combined with Radiotherapy in Nasopharyngeal Carcinoma Patients

Safety and Primary Efficacy of Recombinant Human Adenovirus-P53 Injection on Advanced Solid Tumor

Thermosensitized Effects of Adenovirus-mediated P53 (adp53): Preclinical Study and a Phase II Clinical Trial in China

Application Of Ct-Guided Ad-P53 Intratumoral Injection For Recurrent And Metastatic Gynecologic Cancer Patients Who Received Chemoradiation Therapy

[Effect of Wt P53 Gene Transfection on Sensitivity of Hyperthermia in C6 Glioma Cells].

Multicenter, Open-End, Randomized Controlled Study Using P53 Gene Recombinant Adenovirus Injection (Rad-P53) Combined with Chemotherapy for Orofacial Carcinoma (OFC): Phase IV Clinical Trial—progress Report and Conclusion.

[The Preliminary Study of Recombinant Adenovirus P53 Combined with Transarterial Embolization with Particles for Advanced Hepatocellular Carcinoma].

Intra-Arterial Infusion Of Recombinant Adenoviral Human P53 Gene Combined Chemotherapy For Advanced Oral Cancer: A Phase Ii Double-Blind Randomized Clinical Trial.

Radiofrequency Hyperthermia-Enhanced Herpes Simplex Virus-Thymidine Kinase/ganciclovir Direct Intratumoral Gene Therapy of Hepatocellular Carcinoma

Synergistic Gastric Cancer Inhibition by Chemogenetherapy with Recombinant Human Adenovirus P53 and Epirubicin: an in Vitro and in Vivo Study.

The Curative Effects and Side Effects of Recombinant Human Adenovirus P53 on Transplanted Gastric Cancer Cells in Nude Mice

[Effect of Recombinant Adenovirus-P53 on Growth and Chemosensitivity of Human Lung Adenocarcinoma Cell Lines].

Investigation on the genomic characterization of uterine sarcoma for rAd-p53 combined with chemotherapy treatment.

Effect and Safety of Recombinant Adenovirus-p53 Transfer Combined with Radiotherapy on Long-Term Survival of Locally Advanced Cervical Cancer.